cyclin-d1 has been researched along with Bone-Diseases--Metabolic* in 2 studies
2 other study(ies) available for cyclin-d1 and Bone-Diseases--Metabolic
Article | Year |
---|---|
Deficiency of the intermediate filament synemin reduces bone mass in vivo.
While the type IV intermediate filament protein, synemin, has been shown to play a role in striated muscle and neuronal tissue, its presence and function have not been described in skeletal tissue. Here, we report that genetic ablation of synemin in 14-wk-old male mice results in osteopenia that includes a more than 2-fold reduction in the trabecular bone fraction in the distal femur and a reduction in the cross-sectional area at the femoral middiaphysis due to an attendant reduction in both the periosteal and endosteal perimeter. Analysis of serum markers of bone formation and static histomorphometry revealed a statistically significant defect in osteoblast activity and osteoblast number in vivo. Interestingly, primary osteoblasts isolated from synemin-null mice demonstrate markedly enhanced osteogenic capacity with a concomitant reduction in cyclin D1 mRNA expression, which may explain the loss of osteoblast number observed in vivo. In total, these data suggest an important, previously unknown role for synemin in bone physiology. Topics: Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Cancellous Bone; Cell Differentiation; Cyclin D1; Femur; Intermediate Filament Proteins; Intermediate Filaments; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Osteoblasts; Osteogenesis; RNA, Messenger | 2016 |
ADAR1 ablation decreases bone mass by impairing osteoblast function in mice.
Bone mass is controlled through a delicate balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. We show here that RNA editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) is critical for proper control of bone mass. Postnatal conditional knockout of Adar1 (the gene encoding ADAR1) resulted in a severe osteopenic phenotype. Ablation of the Adar1 gene significantly suppressed osteoblast differentiation without affecting osteoclast differentiation in bone. In vitro deletion of the Adar1 gene decreased expression of osteoblast-specific osteocalcin and bone sialoprotein genes, alkaline phosphatase activity, and mineralization, suggesting a direct intrinsic role of ADAR1 in osteoblasts. ADAR1 regulates osteoblast differentiation by, at least in part, modulation of osterix expression, which is essential for bone formation. Further, ablation of the Adar1 gene decreased the proliferation and survival of bone marrow stromal cells and inhibited the differentiation of mesenchymal stem cells towards osteoblast lineage. Finally, shRNA knockdown of the Adar1 gene in MC-4 pre-osteoblasts reduced cyclin D1 and cyclin A1 expression and cell growth. Our results identify ADAR1 as a new key regulator of bone mass and suggest that ADAR1 functions in this process mainly through modulation of the intrinsic properties of osteoblasts (i.e., proliferation, survival and differentiation). Topics: Adenosine Deaminase; Alkaline Phosphatase; Animals; Bone and Bones; Bone Diseases, Metabolic; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclin A1; Cyclin D1; Gene Silencing; Integrin-Binding Sialoprotein; Male; Mice; Mice, Transgenic; Osteoblasts; Osteocalcin; Osteogenesis; RNA-Binding Proteins; Sp7 Transcription Factor; Transcription Factors | 2013 |